NetworkNewsBreaks – Pressure BioSciences, Inc.
Post# of 1354
(Total Views: 228)
Posted On: 12/28/2017 6:04:14 PM
NetworkNewsBreaks – Pressure BioSciences, Inc.’s (PBIO) Entry into Biopharmaceutical Industry Focus of Zacks Small Cap Research Article
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the global life sciences industry, was recently the focus of a publication by Zacks Small Cap Research titled “PBIO: Enters Biopharmaceutical Quality Control Market”. The publication follows the company’s December 20 announcement regarding the release of redesigned software for its Barocycler 2320EXTREME instrument. The publication notes that the new software was created through collaboration with the company’s biopharmaceutical company customers, therefore entering PBIO into the biopharmaceutical market and accelerating the company’s revenue growth. The Zacks report also discusses PBIO recently acquiring all assets of BaroFold, Inc. The company announced the acquisition of assets including all patents, equipment, and intellectual property (“IP”) relating to BaroFold's PreEMT™ high-pressure protein refolding technology on December 13. The acquired technology is complementary to PBIO’s proprietary Pressure Cycling Technology (“PCT”), increasing the company’s IP in high-pressure technologies. Among other highlights, Zacks noted that this grants the company the ability to operate in several important areas for biologics research and manufacturing.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the global life sciences industry, was recently the focus of a publication by Zacks Small Cap Research titled “PBIO: Enters Biopharmaceutical Quality Control Market”. The publication follows the company’s December 20 announcement regarding the release of redesigned software for its Barocycler 2320EXTREME instrument. The publication notes that the new software was created through collaboration with the company’s biopharmaceutical company customers, therefore entering PBIO into the biopharmaceutical market and accelerating the company’s revenue growth. The Zacks report also discusses PBIO recently acquiring all assets of BaroFold, Inc. The company announced the acquisition of assets including all patents, equipment, and intellectual property (“IP”) relating to BaroFold's PreEMT™ high-pressure protein refolding technology on December 13. The acquired technology is complementary to PBIO’s proprietary Pressure Cycling Technology (“PCT”), increasing the company’s IP in high-pressure technologies. Among other highlights, Zacks noted that this grants the company the ability to operate in several important areas for biologics research and manufacturing.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)